Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic leukaemia.

In response to this news, Dr Maria Gilleece, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust and member of Leukaemia UK's Medical Panel said:

This is a very welcome announcement by NICE and will give hope to patients with CLL, especially those whose disease has progressed beyond initial treatment.

Venetoclax in combination with rituximab is a highly effective therapy that is well tolerated by the majority of patients and importantly does not have to be taken indefinitely in order to maintain the response. 

To find out more follow this link